Lupus eritematoso sistémico posterior a la infección de COVID-19 o a la administración de vacunas: revisión basada en casos.
Saved in:
| Title: | Lupus eritematoso sistémico posterior a la infección de COVID-19 o a la administración de vacunas: revisión basada en casos. |
|---|---|
| Alternate Title: | Systemic lupus erythematosus following COVID-19 infection or vaccine administration: Case-based review. |
| Authors: | Mercado, Ulises1 abimer2013@gmail.com |
| Source: | Medicina Interna de México. ene2025, Vol. 41 Issue 1, p48-56. 9p. |
| Subjects: | SARS-CoV-2, COVID-19, LUPUS erythematosus, SYSTEMIC lupus erythematosus, COVID-19 pandemic |
| Abstract (English): | For many years, a connection between systemic lupus erythematosus and viral infection has been reported. Viruses such as Epstein-Barr virus, cytomegalovirus, parvovirus B-19 and now severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or COVID-19, are linked to a high risk of autoimmune diseases, including systemic lupus erythematosus. Since March 2020 COVID-19 pandemic challenged public health system and the most effective way to reduce COVID-19 infection was immunization. In less than 12 months COVID-19 immunization began. The messenger RNA (Pfizer and Moderna) vaccines were frequently used. S (spike) protein was the primary target to generate neutralizing antibodies in more than 95% of cases. However, immunological phenomena and autoimmune diseases were reported before 30 days following COVID-19 vaccine administration. In this case-based review, the author searched for subjects with a diagnosis of lupus erythematosus following COVID-19 infection or COVID-19 vaccination. Clinical manifestations, personal and family history of autoimmune diseases, number of autoantibodies, and treatment were investigated. Lupus erythematosus activity was measured using Mex-SLEDAI. A clinical history score higher than 7 was considered active lupus erythematosus. [ABSTRACT FROM AUTHOR] |
| Abstract (Spanish): | Durante muchos años se ha reportado una conexión entre el lupus eritematoso sistémico y la infección viral. Los virus Epstein-Barr, citomegalovirus, parvovirus B-19 y ahora el síndrome respiratorio agudo severo asociado con coronavirus 2 (SARS-CoV-2), o COVID-19, se relacionan con alto riesgo de enfermedad autoinmunitaria, incluido el lupus eritematoso sistémico. En marzo de 2020 la pandemia por COVID-19 desafió al sistema de salud pública y, con el fin de contenerla, se inició la vacunación. En menos de 12 meses de la pandemia se inició la inmunización contra COVID-19 con las vacunas de ARN mensajero (Pfizer y Moderna). La proteína S (spike) de COVID-19 se eligió como el blanco primario para generar anticuerpos neutralizantes en más del 95% de los casos. Sin embargo, se reportaron fenómenos inmunológicos y enfermedades autoinmunitarias en los primeros 30 días después de la vacunación. En esta revisión, basada en casos, se buscaron casos con diagnóstico de lupus eritematoso sistémico después de la infección o vacunación contra COVID-19. Se anotaron las manifestaciones clínicas, antecedentes personales y familiares de enfermedades autoinmunitarias, complicaciones, cantidad de autoanticuerpos y tratamiento. La actividad del lupus eritematoso sistémico se midió mediante Mex-SLEDAI. Una puntuación por evaluación de la historia clínica mayor de 7 se consideró lupus eritematoso sistémico activo. [ABSTRACT FROM AUTHOR] |
| Copyright of Medicina Interna de México is the property of Colegio de Medicina Interna de Mexico and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | MedicLatina |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: lth DbLabel: MedicLatina An: 183067423 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Lupus eritematoso sistémico posterior a la infección de COVID-19 o a la administración de vacunas: revisión basada en casos. – Name: TitleAlt Label: Alternate Title Group: TiAlt Data: Systemic lupus erythematosus following COVID-19 infection or vaccine administration: Case-based review. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Mercado%2C+Ulises%22">Mercado, Ulises</searchLink><relatesTo>1</relatesTo><i> abimer2013@gmail.com</i> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Medicina+Interna+de+México%22">Medicina Interna de México</searchLink>. ene2025, Vol. 41 Issue 1, p48-56. 9p. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22SARS-CoV-2%22">SARS-CoV-2</searchLink><br /><searchLink fieldCode="DE" term="%22COVID-19%22">COVID-19</searchLink><br /><searchLink fieldCode="DE" term="%22LUPUS+erythematosus%22">LUPUS erythematosus</searchLink><br /><searchLink fieldCode="DE" term="%22SYSTEMIC+lupus+erythematosus%22">SYSTEMIC lupus erythematosus</searchLink><br /><searchLink fieldCode="DE" term="%22COVID-19+pandemic%22">COVID-19 pandemic</searchLink> – Name: Abstract Label: Abstract (English) Group: Ab Data: For many years, a connection between systemic lupus erythematosus and viral infection has been reported. Viruses such as Epstein-Barr virus, cytomegalovirus, parvovirus B-19 and now severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or COVID-19, are linked to a high risk of autoimmune diseases, including systemic lupus erythematosus. Since March 2020 COVID-19 pandemic challenged public health system and the most effective way to reduce COVID-19 infection was immunization. In less than 12 months COVID-19 immunization began. The messenger RNA (Pfizer and Moderna) vaccines were frequently used. S (spike) protein was the primary target to generate neutralizing antibodies in more than 95% of cases. However, immunological phenomena and autoimmune diseases were reported before 30 days following COVID-19 vaccine administration. In this case-based review, the author searched for subjects with a diagnosis of lupus erythematosus following COVID-19 infection or COVID-19 vaccination. Clinical manifestations, personal and family history of autoimmune diseases, number of autoantibodies, and treatment were investigated. Lupus erythematosus activity was measured using Mex-SLEDAI. A clinical history score higher than 7 was considered active lupus erythematosus. [ABSTRACT FROM AUTHOR] – Name: Abstract Label: Abstract (Spanish) Group: Ab Data: Durante muchos años se ha reportado una conexión entre el lupus eritematoso sistémico y la infección viral. Los virus Epstein-Barr, citomegalovirus, parvovirus B-19 y ahora el síndrome respiratorio agudo severo asociado con coronavirus 2 (SARS-CoV-2), o COVID-19, se relacionan con alto riesgo de enfermedad autoinmunitaria, incluido el lupus eritematoso sistémico. En marzo de 2020 la pandemia por COVID-19 desafió al sistema de salud pública y, con el fin de contenerla, se inició la vacunación. En menos de 12 meses de la pandemia se inició la inmunización contra COVID-19 con las vacunas de ARN mensajero (Pfizer y Moderna). La proteína S (spike) de COVID-19 se eligió como el blanco primario para generar anticuerpos neutralizantes en más del 95% de los casos. Sin embargo, se reportaron fenómenos inmunológicos y enfermedades autoinmunitarias en los primeros 30 días después de la vacunación. En esta revisión, basada en casos, se buscaron casos con diagnóstico de lupus eritematoso sistémico después de la infección o vacunación contra COVID-19. Se anotaron las manifestaciones clínicas, antecedentes personales y familiares de enfermedades autoinmunitarias, complicaciones, cantidad de autoanticuerpos y tratamiento. La actividad del lupus eritematoso sistémico se midió mediante Mex-SLEDAI. Una puntuación por evaluación de la historia clínica mayor de 7 se consideró lupus eritematoso sistémico activo. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Medicina Interna de México is the property of Colegio de Medicina Interna de Mexico and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=183067423 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.24245/mim.v41iEnero.9466 Languages: – Code: spa Text: Spanish PhysicalDescription: Pagination: PageCount: 9 StartPage: 48 Subjects: – SubjectFull: SARS-CoV-2 Type: general – SubjectFull: COVID-19 Type: general – SubjectFull: LUPUS erythematosus Type: general – SubjectFull: SYSTEMIC lupus erythematosus Type: general – SubjectFull: COVID-19 pandemic Type: general Titles: – TitleFull: Lupus eritematoso sistémico posterior a la infección de COVID-19 o a la administración de vacunas: revisión basada en casos. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Mercado, Ulises IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 01 Text: ene2025 Type: published Y: 2025 Identifiers: – Type: issn-print Value: 01864866 Numbering: – Type: volume Value: 41 – Type: issue Value: 1 Titles: – TitleFull: Medicina Interna de México Type: main |
| ResultId | 1 |
